Status:
COMPLETED
DBS Evaluation of Fujirebio INNOTEST® HCV Ab IV
Lead Sponsor:
Foundation for Innovative New Diagnostics, Switzerland
Conditions:
Hepatitis C Virus Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this trial is to evaluate the performance of the Fujirebio INNOTEST® HCV Ab IV using simpler collection methods such as fingerstick and venous whole blood collection on dried blood spots (...
Detailed Description
Access to Hepatitis C virus (HCV) screening in resource-limited settings should be enabled not only through the provision of point-of-care screening tests, but also through the possibility of collecti...
Eligibility Criteria
Inclusion
- Aged ≥18 years
- Provision of written informed consent
- Routine RDT reactive or non-reactive and recruitment target not yet met
- No history of HCV treatment
Exclusion
- Unwilling to provide required volume of fingerstick blood and venous whole blood
- Participants already enrolled in the trial
Key Trial Info
Start Date :
January 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2020
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04317729
Start Date
January 30 2020
End Date
May 31 2020
Last Update
July 7 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Astar Medical Centre
Lviv, Ukraine, 79000
2
Lviv Regional Public Health Centre
Lviv, Ukraine, 79026